PeptidePreclinical
Ara 290
Also known as: Cibinetide
Tissue-Protective Peptide | Innate Repair Receptor Agonist
Overview
Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.
Key benefits
- Proven tissue protection
- Nerve regeneration
- Anti-inflammatory effects
- Excellent safety profile in clinical trials
Mechanism of action
Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.
Molecular data
- Type
- Engineered peptide
- Half-life
- ~20 minutes (SubQ), ~2 minutes (IV)
Sequence
pGlu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Indications
What the research community uses this compound for, with self-reported effectiveness.
Neuroprotection
Tissue Repair
Anti-Inflammatory
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 4 mg daily | Once daily | — |
| — | 1-8 mg daily | Once daily | — |
| — | 2 mg | 3x weekly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Excellent safety profile in clinical trials with no serious drug-related adverse events
Contraindications
- Recent anti-TNF therapy (within 6 months)
- EPO use (within 2 months)
- Pregnancy
- BMI > 34 kg/m²
Monitoring
- Injection site reactions
- Anti-drug antibody development
- Blood count changes
- No hematopoietic effects or polycythemia risk unlike erythropoietin
References
Primary literature and clinical-trial data informing this entry.